Journal article
Etidronate for hypercalcemia of malignancy and osteoporosis
American family physician, v 43(6), pp 2155-2159
01 Jun 1991
PMID: 1904188
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
The biphosphonates are becoming well established as effective agents for the treatment of metabolic bone diseases. Etidronate disodium is the only biphosphonate approved by the U.S. Food and Drug Administration. Accepted indications for etidronate therapy are symptomatic Paget's disease, heterotopic ossification and hypercalcemia of malignancy. An unapproved, but apparently successful use is treatment of postmenopausal osteoporosis. Both oral and intravenous preparations are available. Newer biphosphonates, which may be more efficacious and less toxic than etidronate, are being studied.
Metrics
1 Record Views
Details
- Title
- Etidronate for hypercalcemia of malignancy and osteoporosis
- Creators
- E HorowitzJ L MillerL I Rose
- Publication Details
- American family physician, v 43(6), pp 2155-2159
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Management
- Web of Science ID
- WOS:A1991FP89400026
- Scopus ID
- 2-s2.0-0025768801
- Other Identifier
- 991019184054304721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Primary Health Care